At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 263 enrolled
Drug / intervention
LY2409021 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of LY2409021 in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating LY2409021 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 263 participants across 40 sites in 7 countries.
Detailed Summary
LY2409021 is being evaluated for possible treatment in type 2 diabetes. This study is designed to compare LY2409021 given alone or given in combination with metformin against placebo the change in hemoglobin A1c after a 24-week treatment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesGermany, Italy, Puerto Rico, Romania, Slovakia, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartJan 2011
Primary CompletionFeb 2012
Study CompletionMar 2012
TodayJul 2026
First PostedNov 16, 2010
Enrollment StartJan 1, 2011
Primary CompletionFeb 1, 2012
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.6 years ago
Interventions
LY2409021drug
Administered Orally
Placebodrug
Administered Orally